Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
http://www.communityoncology.net/journa ... 701023.pdf
Multikinase inhibitors (MKIs, eg, sorafenib, sunitinib, cediranib etc) are oral anticancer agents associated with handfoot
skin reaction (HFSR), a cutaneous adverse event affecting 20%–40% of patients treated with these
drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened
duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently
provided the first consensus recommendations for the management of MKI-associated HFSR.
Recommend. for the Management of hand-foot skin reaction
Re: Recommend. for the Management of hand-foot skin reaction
Link no longer works. Maybe this is a similar article to what you had posted:
http://www.oncologypractice.com/index.p ... ews]=58371
May need to cut and paste as the BBS doesn't like the brackets in the URL...
http://www.oncologypractice.com/index.p ... ews]=58371
May need to cut and paste as the BBS doesn't like the brackets in the URL...
Re: Recommend. for the Management of hand-foot skin reaction
I found the article again and used tinyurl to preserve the link:
Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
http://tinyurl.com/bwzfapo
very good article for anyone taking TKI (they call them MKI now).
Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
http://tinyurl.com/bwzfapo
very good article for anyone taking TKI (they call them MKI now).
Olga